Vaccinia virus vectors: new strategies for producing recombinant vaccines.
The development and continued refinement of techniques for the efficient insertion and expression of heterologous DNA sequences from within the genomic context of infectious vaccinia virus recombinants are among the most promising current approaches towards effective immunoprophylaxis against a variety of protozoan, viral, and bacterial human pathogens. Because of its medical relevance, this area is the subject of intense research interest and has evolved rapidly during the past several years. This review (i) provides an updated overview of the technology that exists for assembling recombinant vaccinia virus strains, (ii) discusses the advantages and disadvantages of these approaches, (iii) outlines the areas of outgoing research directed towards overcoming the limitations of current techniques, and (iv) provides some insight (i.e., speculation) about probable future refinements in the use of vaccinia virus as a vector.
Department of Microbiology, Oregon State University, Corvallis 97331-3804.
D E
DE
Hruby
D000818:Animals; D006801:Humans; D014612:Vaccines; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines
D014612:Vaccines; D014614:Vaccines, Synthetic; D014765:Viral Vaccines